

ABOUT YOUR TREATMENT

You have been prescribed Lixiana[®], an anticoagulant medicine, which thins your blood and helps prevent you from suffering blood clots. It is important that you take your medication exactly as instructed by your doctor.

- If you miss a dose, take it immediately and then continue the following day as normal – do not take double the prescribed dose in a single day.

- Do not start any other medications (including over the counter) without consulting your doctor.
- Do not stop taking Lixiana[®] without consulting your doctor as this can increase your risk of developing a blood clot.
- Please read the Patient Information Leaflet found inside each pack of Lixiana[®].

WHEN TO SEEK MEDICAL ADVICE

RISK OF BLEEDING

Taking an anticoagulant medicine such as Lixiana[®] can increase your risk of bleeding. It is therefore important to be aware of the possible signs and symptoms of bleeding and to speak to your doctor immediately if you experience any of the following:

- Bruising or bleeding under the skin
- Blood in the urine
- Coughing up blood

- Vomiting blood or material that looks like ground coffee
- Nose bleeds or cuts that take a long time to stop bleeding
- Tar-coloured stools
- Dizziness or sudden headache
- Unexplained tiredness
- Abnormal vaginal bleeding, including heavier or prolonged menses

Please talk to your doctor if you experience any unusual symptoms.

PATIENT ALERT CARD

Lixiana[®]
film-coated tablets
edoxaban

Please keep this card with you at all times.

Present it to your healthcare professional, pharmacist, surgeon or dentist before any medical treatment or intervention.


49 mm

50 mm

51 mm

53 mm

52 mm

<p>PATIENT INFORMATION</p> <p>Patient name:</p> <p>Date of birth:</p> <p>In case of emergency, please contact: Name: Phone no:</p>	<p>TREATMENT INFORMATION (To be completed by physician)</p> <p>Lixiana[®] has been prescribed at a once-daily dose of: mg</p> <p>S started on: / (mm/yy)</p> <p>B lood type:</p> <p>Other medications/conditions:</p>	<p>PRESCRIBER INFORMATION</p> <p>For more information or in case of emergency, please contact: Physician's name:</p> <p>Phone number, practice stamp:</p> <p>Signature of physician:</p>	<p>INFORMATION FOR HEALTHCARE PROFESSIONALS</p> <ul style="list-style-type: none"> • Lixiana[®] is an oral anticoagulant factor Xa inhibitor. • When an invasive procedure is required, Lixiana[®] should be stopped at least 24 hours beforehand, and appropriate caution exercised. • Lixiana[®] may increase the risk of bleeding. In case of clinically significant bleeding, stop treatment immediately. • Coagulation tests such as INR, prothrombin time (PT), or activated partial thromboplastin time (aPTT) 	<p>are not a useful measure of the effect of Lixiana[®]. However, a calibrated anti-Factor Xa assay may help inform clinical decisions.</p> <p>Please consult the Summary of Product Characteristics (SPC) for more information</p> <div style="border: 1px solid black; padding: 5px;"> <p>For any information about this medicine, please contact Saudi Arabian Japanese pharmaceutical company limited Jeddah – Saudi Arabia P.O. Box: 42600, Jeddah 21551, KSA Tel: + 966 12 606 6667 www.sajapharma.com This leaflet was last revised in (March/2017); version number (00) -To report any side effect (s) • Saudi Arabia : The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: + 966 11 205 7662 o Toll free phone: 8002490000 o E-mail: npc.drug@sfga.gov.sa o Website: www.sfga.gov.sa/npc</p> </div> <p style="text-align: center;"></p>
52 mm	53 mm	51 mm	50 mm	49 mm